- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00353119
A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Phase 3 Study With a Placebo-Controlled, Double-blind, on the Safety and Efficacy of Etanercept in Palmo-Plantar Pustulosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a placebo-controlled double blind study. Patients will be randomized to receive etanercept versus placebo in a 2:1 fashion for the first 3 months. All patients will receive etanercept in the last 3 months.
Patients with active PPP will be included. A washout of 4 weeks for systemic medications and 2 weeks for Psoralen Ultra Violet A (PUVA) therapy will be required. A washout period of 2 weeks will be required for all other topical medications. The Palmoplantar pustulosis severity index (PPPASI) will be used to evaluate severity. Only patients with a severity score of 8 or more on hands and/or feet will be included. Safety will be assessed by performing physical examinations, evaluation of adverse events and biological parameters (complete blood count (CBC), chemistry, urinalysis).
High quality digital medical photographs will be taken at baseline, 3 months and 6 months.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1V 4X7
- Centre de Recherche Dermatologique Du Quebec Metropolitain
-
-
Quebec
-
Laval, Quebec, Canada, H7S 2C6
- Innovaderm Research Incorporated
-
Montreal, Quebec, Canada, H2K 4L5
- Innovaderm Research Incorporated
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Palmoplantar pustulosis with a severity score of at least 8 on hands and-or feet
- Age 18 years or older
- Patient who would benefit from systemic therapy
- Unless surgically sterile (or at least 1 year post-menopausal for women) patients (heterosexual men and women) must have used a effective method of contraception for at least 30 days before the start of the study drug and until at least 1 month after the last drug administration
- Informed consent obtained
- Normal or non clinically significant chest X ray taken within 6 months of screening
- Negative serum pregnancy test at screening and negative urine pregnancy test at day 0 for women of childbearing potential
- Negative personal history of tuberculosis
- Presence of PPP for more than 6 months
- Subject must be willing to inject themselves subcutaneously.
- Negative PPD results
Exclusion Criteria:
- Use of topical steroids, topical tar preparations, or other topical anti PPP or anti-psoriatic preparations within the past two weeks
- Unstable forms of psoriasis (acute guttate psoriasis, psoriatic erythroderma, generalized pustular psoriasis)
- At the investigator's discretion any significant infection within 30 days of screening or a patient at risk of septicemia
- Presence of acute forms of tinea pedis and other causes of pustular eruptions of the palms and soles apart from PPP based on clinical evaluation
- Evidence of any skin condition that would interfere with the evaluation of PPP
- Use of investigational drugs within the past four weeks
- Use of systemic anti-PPP or anti-psoriatic drugs such as steroids, retinoids, or methotrexate within the past four weeks
- Use of parenteral systemic antibiotics within the past four weeks
- Use of cyclosporine within the past four weeks
- Use of ultraviolet light therapy (UVB, nbUVB or PUVA) within the past two weeks
- An unstable or serious medical condition
- Known sero-positivity for the HIV virus
- Known hypersensitivity to etanercept or one of its components
- Receipt of live attenuated vaccines 12 weeks or less before Day 0 and during the course of the study
- Pregnant or breast feeding female subject
- Any significant medical condition that might cause this study to be detrimental to the patient
- At the investigator's discretion current or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol
- Presence of congestive heart failure
- Presence of a demyelinating disorder (optic neuritis, multiple sclerosis or other)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo then etanercept
Patients randomized to initiate the study with placebo for the first 12 weeks - Group 1 then crossed over to etanercept 50mg twice weekly for weeks 12 to 24
|
Patients received placebo subcutaneously twice weekly
Other Names:
Patients received etanercept 50 mg subcutaneously twice weekly
Other Names:
|
Active Comparator: Etanercept
Patients randomized to etanercept - Group 2. Patients received etanercept 50 mg subcutaneously twice weekly for 24 weeks
|
Patients received etanercept 50 mg subcutaneously twice weekly
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover
Time Frame: 12 weeks
|
Comparison of the percentage change in Palmoplantar pustulosis severity index PPPASI) at 12 weeks in patients treated with placebo or etanercept PPPASI = (E + I + D)Area X 0.2 (R palm) + (E + I + D) Area X 0.2 (L palm) + (E + I + D) Area X 0.3 (R sole) + (E + I + D) Area X 0.3 (L sole). Erythema, pustules and desquamation are evaluated on a scale of 0 to 4 while area is evaluated on a scale of 0 to 6. The PPPASI score can vary from 0 (absence of disease) to 72 (most severe palmoplantar psoriasis possible). |
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Events
Time Frame: 28 weeks
|
Study the safety of etanercept in patients with PPP by collecting adverse events from the screening visit until week 28.
For a given AE, a subject will be counted once even if he or she has experienced multiple episodes for that particular AE.
An adverse event is any untoward medical occurrence including any clinically significant abnormal laboratory values or variation from the baseline condition to the last visit (week 28) in a patient receiving a pharmaceutical product, without regards to the possibility of a causal relationship with this treatment.
|
28 weeks
|
Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPPASI)
Time Frame: 24 weeks
|
Evaluate efficacy using palmoplantar pustulosis area and severity index (PPPASI) in patient with palmoplantar pustulosis treated with etanercept for 6 months PPPASI = (E + I + D)Area X 0.2 (R palm) + (E + I + D) Area X 0.2 (L palm) + (E + I + D) Area X 0.3 (R sole) + (E + I + D) Area X 0.3 (L sole). Erythema, pustules and desquamation are evaluated on a scale of 0 to 4 while area is evaluated on a scale of 0 to 6. The PPPASI score can vary from 0 (absence of disease) to 72 (most severe palmoplantar psoriasis possible). |
24 weeks
|
Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPPASI) After Crossover
Time Frame: 12 weeks
|
Evaluate efficacy using palmoplantar pustulosis area and severity index (PPPASI) in patient with palmoplantar pustulosis treated with etanercept for 6 months PPPASI = (E + I + D)Area X 0.2 (R palm) + (E + I + D) Area X 0.2 (L palm) + (E + I + D) Area X 0.3 (R sole) + (E + I + D) Area X 0.3 (L sole). Erythema, pustules and desquamation are evaluated on a scale of 0 to 4 while area is evaluated on a scale of 0 to 6. The PPPASI score can vary from 0 (absence of disease) to 72 (most severe palmoplantar psoriasis possible). |
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Bissonnette, MD MSc FRCPC, Innovaderm Research Incorporated
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Skin Diseases, Papulosquamous
- Psoriasis
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Etanercept
Other Study ID Numbers
- 2.3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Palmoplantaris Pustulosis
-
AmgenCompletedPalmoplantaris PustulosisJapan
-
Janssen Pharmaceutical K.K.Completed
-
The Guenther Dermatology Research CentreBiogenCompletedPsoriasis | Palmoplantaris Pustulosis | Pustulosis of Palms and Soles | Pustular Psoriasis of Palms and Soles | Pustulosis Palmaris et PlantarisCanada
-
Lenzi Egisto S.P.A.TerminatedPustulosis of Palms and SolesItaly
-
AbbVieCompleted
-
Boehringer IngelheimCompletedPalmoplantar Pustulosis (PPP)United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Hungary, Netherlands, Czechia, Poland
-
Janssen Pharmaceutical K.K.Active, not recruiting
-
Boehringer IngelheimTerminatedPalmoplantar PustulosisUnited Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Czechia, Hungary, Poland
-
Baylor Research InstituteJanssen Services, LLC; Dermatology Research InstituteCompleted
-
Brigham and Women's HospitalUniversity of PennsylvaniaRecruiting
Clinical Trials on Placebo comparator
-
Eisai Inc.CompletedAlzheimer's DiseaseUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Merck Sharp & Dohme LLCWithdrawn
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCTerminated
-
TiumBio Co., Ltd.RecruitingEndometriosisCzechia, Italy, Russian Federation, Poland, Ukraine
-
Merck Sharp & Dohme LLCTerminatedType 2 Diabetes
-
Cognition TherapeuticsRecruitingAge-Related Macular DegenerationUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted